Suchergebnisse - "Schmid, Peter"

PubPharm (633)

51

Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply

enthalten in: Lancet (London, England) | 2021

von Cortes, J. | Rugo, H. | Guo, Z. | +2

CommentOn: Lancet. 2021 Jul 3;398(10294):24. - PMID 34217392

52

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain) : a multicentre, randomised, open-label, non-comparative, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Pérez-García, J. | Gebhart, G. | Ruiz Borrego, M. | +20

CommentIn: Future Oncol. 2022 Oct;18(33):3677-3688. - PMID 36300423

53

Emerging drugs for the treatment of triple-negative breast cancer : a focus on phase II immunotherapy trials

enthalten in: Expert opinion on emerging drugs | 2021

von Hall, P. | Schmid, P.

54

Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Quintana, �. | Peg, V. | Prat, A. | +15

55

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC") : a randomized multicenter study

enthalten in: NPJ breast cancer | 2021

von Vahdat, L. | Schmid, P. | Forero-Torres, A. | +15

56

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY) : An open-label, multicentre, single-arm, phase Ⅱ trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Pérez-García, J. | Llombart-Cussac, A. | G Cortés, M. | +16

57

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

enthalten in: EClinicalMedicine | 2021

von Falchook, G. | Infante, J. | Arkenau, H. | +15

58

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2021

von Bardia, A. | Hurvitz, S. | Tolaney, S. | +117

CommentIn: Nat Rev Clin Oncol. 2021 Jun;18(6):322. - PMID 33931767

59

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Winer, E. | Lipatov, O. | Im, S. | +18

CommentIn: Lancet Oncol. 2021 Jun;22(6):e224. - PMID 34087134

60

A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction

enthalten in: Breast (Edinburgh, Scotland) | 2021

von Varghese, J. | Gohari, S. | Rizki, H. | +5